Repligen | RGEN - Себестоимость





Себестоимость Изменить Дата
Agilent USD 845M 7M 2026-03
Align Technology USD 303.5M 60.47M 2026-03
Bio Techne USD 103.13M 1.47M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Bruker USD 443.6M 84.4M 2026-03
Charles River Laboratories USD 716.51M 5.76M 2026-03
Danaher USD 2.36B 512M 2026-03
Dentsply International USD 453M 65M 2026-03
General Electric Aerospace USD 8.15B 764M 2026-03
Henry Schein USD 2.3B 145M 2026-03
Illumina USD 370M 30M 2026-03
IQVIA Holdings USD 3.08B 161M 2026-03
Mettler Toledo International USD 410.92M 63.05M 2026-03
Myriad Genetics USD 63M 1.1M 2025-12
OraSure Technologies USD 15.43M 113K 2025-12
Pacific Biosciences Of California USD 28.9M 10M 2025-12
Pfizer USD 4.59B 1.7B 2026-03
Repligen USD 85.97M 8.11M 2026-03
Revvity USD 323.46M 26.93M 2026-03
Standard Biotools USD 9.84M 2.58M 2026-03
Thermo Fisher Scientific USD 6.96B 620M 2026-03
Waters USD 725M 350.06M 2026-03
West Pharmaceutical Services USD 548.5M 47.4M 2026-03